Rockefeller Capital Management
GMAB icon

Rockefeller Capital Management’s Genmab GMAB Stock Holding History

Rockefeller Capital Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$464K Buy
16,885
+812
+5% +$21.6K ﹤0.01% 2123
2026
Q1 		$431K Buy
16,073
+3,501
+28% +$105K ﹤0.01% 2060
2025
Q4 		$387K Buy
12,572
+10,376
+472% +$323K ﹤0.01% 2036
2025
Q3 		$67.4K Sell
2,196
-10,735
-83% -$262K ﹤0.01% 2767
2025
Q2 		$267K Buy
+12,931
New +$265K ﹤0.01% 1674
2025
Q1 		– Sell
-14,894
Closed -$316K – 1692
2024
Q4 		$316K Sell
14,894
-1,280
-8% -$28.1K ﹤0.01% 1589
2024
Q3 		$397K Sell
16,174
-871
-5% -$23.3K ﹤0.01% 1497
2024
Q2 		$431K Sell
17,045
-4,450
-21% -$126K ﹤0.01% 1483
2024
Q1 		$643K Buy
21,495
+3,224
+18% +$94.7K ﹤0.01% 1394
2023
Q4 		$582K Sell
18,271
-648
-3% -$20.3K ﹤0.01% 1307
2023
Q3 		$667K Buy
18,919
+4,945
+35% +$188K ﹤0.01% 1223
2023
Q2 		$531K Sell
13,974
-4,534
-24% -$181K ﹤0.01% 1317
2023
Q1 		$698K Buy
18,508
+310
+2% +$11.9K ﹤0.01% 1207
2022
Q4 		$770K Buy
18,198
+4,009
+28% +$165K ﹤0.01% 1102
2022
Q3 		$454K Buy
14,189
+904
+7% +$31.7K ﹤0.01% 1306
2022
Q2 		$430K Sell
13,285
-5
-0% -$162 ﹤0.01% 1328
2022
Q1 		$480K Sell
13,290
-53
-0.4% -$1.82K ﹤0.01% 1326
2021
Q4 		$527K Sell
13,343
-308
-2% -$12.8K ﹤0.01% 1292
2021
Q3 		$596K Buy
13,651
+2,493
+22% +$112K ﹤0.01% 1195
2021
Q2 		$455K Sell
11,158
-1,978
-15% -$76.3K ﹤0.01% 1228
2021
Q1 		$430K Buy
13,136
+3,176
+32% +$119K ﹤0.01% 1072
2020
Q4 		$404K Buy
9,960
+6,858
+221% +$256K ﹤0.01% 984
2020
Q3 		$112K Buy
3,102
+424
+16% +$15.3K ﹤0.01% 1214
2020
Q2 		$91K Buy
2,678
+1,871
+232% +$51K ﹤0.01% 1196
2020
Q1 		$17K Buy
807
+432
+115% +$9.63K ﹤0.01% 1563
2019
Q4 		$8K Sell
375
-282
-43% -$6.15K ﹤0.01% 1665
2019
Q3 		$13K Buy
+657
New +$12.9K ﹤0.01% 1344

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Rockefeller Capital Management's GMAB Position: Q2 2026 in Review

Rockefeller Capital Management increased its Genmab (GMAB) stake by 5.1% in Q2 2026, buying an estimated $21.6K and bringing the position to 16,885 shares worth $464K. The position accounts for ﹤0.01% of the portfolio, ranked #2123.

Rockefeller Capital Management first reported a position in GMAB in Q3 2019 and has held it in 27 quarters since. The position peaked at $770K in Q4 2022. 291 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Rockefeller Capital Management held 16,885 shares of Genmab worth $464K as of Q2 2026.
  • Rockefeller Capital Management bought 812 Genmab shares in Q2 2026, an estimated $21.6K.
  • Genmab made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #2123 holding.
  • Rockefeller Capital Management first reported a position in Genmab in Q3 2019 and has held it in 27 quarters since.
  • Rockefeller Capital Management's Genmab position peaked at $770K in Q4 2022.
  • 291 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.